Cited by 4,427Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Open access

Greenberg, Peter, Cox, Christopher, LeBeau, Michelle M., Fenaux, Pierre, Morel, Pierre, Sanz, Guillermo, Sanz, Miguel, Vallespi, Teresa, Hamblin, Terry, Oscier, David, Ohyashiki, Kazuma, Toyama, Keisuke, Aul, Carlo, Mufti, Ghulam, Bennett, John·1997·Blood

DOI 10.1182/blood.v89.6.2079

Open this paper in CoChat — free account Open PDF

Abstract

Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: “good” outcomes were normal, −Y alone, del(5q) alone, del(20q) alone; “poor” outcomes were complex (ie, ≥3 abnormalities) or chromosome 7 anomalies; and “intermediate” outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT-1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood.v89.6.2079

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Self-citation
Myelodysplastic syndromes: a scoring system with prognostic significance
Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507
Self-citation
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431
Self-citation
Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients
Sanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406
Self-citation
The 5q− anomaly
BERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300
Self-citation
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265
Self-citation
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes
Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246
Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia
Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232

Show all 33 references

Sorted by citations

Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Self-citation
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Self-citation
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,191
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D. A., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,814
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
Decitabine improves patient outcomes in myelodysplastic syndromes
Kantarjian, H. M., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M. X., DiPersio, J. F., Klimek, V. M., Slack, J. L., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,539
Self-citation
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Self-citation
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J., Barosi, G., et al. (2008) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,256
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
Malcovati, L., Germing, U., Kuendgen, A., Porta, M. G. D., Pascutto, C., Invernizzi, R., Giagounidis, A. A. N., Hildebrandt, B., BERNASCONI, P. P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,029
Self-citation
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
Dispenzieri, A. A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Self-citation
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
Armand, P. A., Kim, H. T., Logan, B. R., Wang, Z. P., Alyea, E. P., Kalaycio, M. E., Maziarz, R. T., Antin, J. H., Soiffer, R. J., Weisdorf, D. J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552984 · Cited by 951
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200008 · Cited by 867
Self-citation
Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., BERNASCONI, P. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 867
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J. A., Jongen‐Lavrencic, M., von Lilienfeld‐Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
Haase, D. T., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kündgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-082404 · Cited by 796
Self-citation
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D. J., Abbott, R. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 795
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Schanz, J., Tüchler, H., Solé, F. G., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6394 · Cited by 688
Self-citation
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Scott, B. L., Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7091 · Cited by 674
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
Cutler, C. S. (2004) · Blood · doi:10.1182/blood-2004-01-0338 · Cited by 673
Context is everything: aneuploidy in cancer
Ben‐David, U., & Amon, A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0171-x · Cited by 683
Myelodysplastic Syndromes
Tefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 685
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Malcovati, L., Hellström‐Lindberg, E., Bowen, D., Adès, L., Čermák, J., del Cañizo, C., Porta, M. G. D., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 682
Self-citation
Report of an international working group to standardize response criteria for myelodysplastic syndromes.
Cheson, B. D., Bennett, J. M., Kantarjian, H. M., Pinto, A., Schiffer, C. A., Nimer, S. D., Löwenberg, B., Beran, M., de Witte, T. M., Stone, R. M., et al. (2000) · PubMed · Cited by 666
Self-citation
Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients
Wijermans, P., Lübbert, M., Verhoef, G. E. G., Bosly, A., Ravoet, C., André, M. P. E., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 566
Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Gelsi‐Boyer, V., Trouplin, V., Adélaı̈de, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prébet, T., Nezri, M., Sainty, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07697.x · Cited by 589
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Lübbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A. A. N., Selleslag, D., Labar, B., Germing, U., Salih, H. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9245 · Cited by 557
Self-citation
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia‐Manero, G., Buckstein, R. J., Santini, V., Díez‐Campelo, M., Finelli, C., Cazzola, M., İlhan, O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908892 · Cited by 551
Self-citation
Telomere and telomerase in stem cells
Hiyama, E., & Hiyama, K. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603671 · Cited by 573
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Itzykson, R., Kosmider, O., Renneville, A., Gelsi‐Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne‐Rauzy, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3314 · Cited by 559
Self-citation
Myelodysplastic syndromes
Ma, X., Does, M. B., Raza, A., & Mayne, S. T. (2007) · Cancer · doi:10.1002/cncr.22570 · Cited by 537
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment
Daskalakis, M., Nguyen, T. T., Nguyen, C. T., Guldberg, P., Köhler, G., Wijermans, P., Jones, P. A., & Lübbert, M. (2002) · Blood · doi:10.1182/blood.v100.8.2957 · Cited by 513
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
Valent, P., Horny, H., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P. L., Haferlach, T., Haase, D. T., Kölb, H.-J., Krieger, O., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.11.009 · Cited by 514
Self-citation
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Malcovati, L., Papaemmanuil, E., Bowen, D., Boultwood, J., Porta, M. G. D., Pascutto, C., Travaglino, E., Groves, M. J., Godfrey, A. L., Ambaglio, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377275 · Cited by 506
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Cortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O. G., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0312-9 · Cited by 496
Myelodysplastic Syndromes
Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 508
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 493
Self-citation
Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
McClune, B. L., Weisdorf, D. J., Pedersen, T. L., da Silva, G. T., Tallman, M. S., Sierra, J., DiPersio, J. F., Keating, A., Gale, R. P., George, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4821 · Cited by 487
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Adès, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8135 · Cited by 475
Self-citation
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Kantarjian, H. M., O'Brien, S. M., Ravandi, F., Cortes, J. E., Shan, J., Bennett, J. M., List, A. F., Fenaux, P., Sanz, G. F., Issa, J. J., et al. (2008) · Cancer · doi:10.1002/cncr.23697 · Cited by 482
Self-citation
Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms
Gore, S. D., Baylin, S. B., Sugar, E. A., Carraway, H. E., Miller, C. B., Carducci, M. A., Grever, M. R., Galm, O., Dauses, T., Karp, J. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0080 · Cited by 478
HAWAI'I MEDICAL JOURNAL
Murayama, K. M. (2007) · Cited by 477
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
Itzykson, R., Kosmider, O., Cluzeau, T., Mas, V. M., Dreyfus, F., Beyne‐Rauzy, O., Quesnel, B., Vey, N., Gelsi‐Boyer, V., Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 480
Self-citation
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463
Self-citation
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life
Hellström‐Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I. M. S., Dybedal, I., Grimfors, G., Hesse‐Sundin, E., Hjorth, M., Kanter‐Lewensohn, L. R., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04153.x · Cited by 456
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Bejar, R. L., Stevenson, K. E., Caughey, B. A., Abdel-Wahab, O. I., Steensma, D. P., Galili, N., Raza, A., Kantarjian, H. M., Levine, R. L., Neuberg, D. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7379 · Cited by 450
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
Hasle, H., Niemeyer, C. M., Chessells, J. M., Baumann, I., Bennett, J. M., Kerndrup, G. B., & Head, D. R. (2003) · Leukemia · doi:10.1038/sj.leu.2402765 · Cited by 433
Self-citation
Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes
Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Shiozawa, Y., Kon, A., Alpermann, T., Yoshida, K., et al. (2013) · Blood · doi:10.1182/blood.v122.21.521.521 · Cited by 430
Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
de Lima, M., Giralt, S., Thall, P. F., Silva, L. D. P., Jones, R. B., Komanduri, K. V., Braun, T. M., Nguyen, H. Q., Champlin, R. E., & Garcia‐Manero, G. (2010) · Cancer · doi:10.1002/cncr.25500 · Cited by 427
Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
Kaminskas, E., Farrell, A. M., Abraham, S., Baird, A., Hsieh, L.-S., Lee, S., Leighton, J. K., Patel, H. R., Rahman, A., Sridhara, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2135 · Cited by 424
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, H. J., Dreisbach, L. P., Schiffer, C. A., Stone, R. M., Greenberg, P. L., et al. (2007) · Blood · doi:10.1182/blood-2007-01-068833 · Cited by 421
Self-citation
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Lima, M. J. G. D., Couriel, D. R., Thall, P. F., Wang, X., Madden, T. L., Jones, R. B., Shpall, E. J., Shahjahan, M., Pierre, B., Giralt, S. A., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0414 · Cited by 415
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 428
Cytarabine Dose for Acute Myeloid Leukemia
Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Biemond, B. J., Gratwohl, A. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010222 · Cited by 408
Myelodysplasia
Heaney, M. L., & Golde, D. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905273402107 · Cited by 399
Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation
Sorror, M. L., Sandmaier, B. M., Storer, B. E., Maris, M. B., Baron, F., Maloney, D. G., Scott, B. L., Deeg, H. J., Appelbaum, F. R., & Storb, R. F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7865 · Cited by 398
Myelodysplastic syndromes
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 418
Self-citation
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
Onida, F., Kantarjian, H. M., Smith, T. L., Ball, G., Keating, M. J., Estey, E. H., Glassman, A. B., Albitar, M. X., Kwari, M. I., & Beran, M. (2002) · Blood · doi:10.1182/blood.v99.3.840 · Cited by 385
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D. W., Yakoub‐Agha, I., Mufti, G. J., Fenaux, P., Sanz, G. F., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 385
Self-citation
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., Dartigeas, C., Legros, L., et al. (2010) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 381
Self-citation
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A. M., Kar, S. A., Jerez, A., Przychodzen, B. P., Bupathi, M., Guinta, K. M., Afable, M. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399774 · Cited by 387
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Elena, C., Gallì, A., Such, E., Meggendorfer, M., Germing, U., Rizzo, E., Cervera, J., Molteni, E., Fasan, A., Schuler, E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-714030 · Cited by 375
Self-citation
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
Martino, R. (2006) · Blood · doi:10.1182/blood-2005-11-4503 · Cited by 363
The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS
Parker, J. E., Mufti, G. J., Rasool, F., Mijović, A., Devereux, S., & Pagliuca, A. (2000) · Blood · doi:10.1182/blood.v96.12.3932 · Cited by 361
Self-citation
Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation
Wells, D. A., Benesch, M., Loken, M. R., Vallejo, C. T., Myerson, D., Leisenring, W. M., & Deeg, H. J. (2003) · Blood · doi:10.1182/blood-2002-09-2768 · Cited by 360
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
Yoshizato, T., Nannya, Y., Atsuta, Y., Shiozawa, Y., Iijima‐Yamashita, Y., Yoshida, K., Shiraishi, Y., Suzuki, H., Nagata, Y., Sato, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-12-754796 · Cited by 352
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping
Haferlach, C., Dicker, F., Schnittger, S., Kern, W., & Haferlach, T. (2007) · Leukemia · doi:10.1038/sj.leu.2404935 · Cited by 350
Myelodysplastic Syndromes — Coping with Ineffective Hematopoiesis
Cazzola, M., & Malcovati, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048266 · Cited by 345
Myelodysplastic syndromes: the complexity of stem-cell diseases
Corey, S. J., Minden, M. D., Barber, D. L., Kantarjian, H. M., Wang, J. C. Y., & Schimmer, A. D. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2047 · Cited by 346
Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression
Quesnel, B., Guillerm, G., Vereecque, R., Wattel, E., Preudhomme, C., Bauters, F., Vanrumbeke, M., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.8.2985.2985_2985_2990 · Cited by 341
Self-citation
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
Mufti, G. J., Bennett, J. M., Goasguen, J., Bain, B. J., Baumann, I., Brunning, R. D., Cazzola, M., Fenaux, P., Germing, U., Hellström‐Lindberg, E., et al. (2008) · Haematologica · doi:10.3324/haematol.13405 · Cited by 337
Self-citation
Myelodysplastic syndromes
Nimer, S. D. (2008) · Blood · doi:10.1182/blood-2007-08-078139 · Cited by 339
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Park, S., Grabar, S., Kelaïdi, C., Beyne‐Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096370 · Cited by 331
Self-citation
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
Such, E., Germing, U., Malcovati, L., Cervera, J., Kuendgen, A., Porta, M. G. D., Nomdedeu, B., Arenillas, L., Luño, E., Xicoy, B., et al. (2013) · Blood · doi:10.1182/blood-2012-08-452938 · Cited by 320
Self-citation
A prognostic score for patients with lower risk myelodysplastic syndrome
Garcia‐Manero, G., Shan, J., Faderl, S., Cortes, J. E., Ravandi, F., Borthakur, G. M., Wierda, W. G., Pierce, S. A., Estey, E. H., Liu, J., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405070 · Cited by 316
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
Gondek, L. P., Tiu, R. V., O’Keefe, C. L., Sekeres, M. A., Theil, K. S., & Maciejewski, J. P. (2007) · Blood · doi:10.1182/blood-2007-05-092304 · Cited by 318
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Bejar, R. L., Levine, R. L., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 309
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J. M., et al. (2001) · Blood · doi:10.1182/blood.v98.4.958 · Cited by 304
Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y. P., Carlsson, M., Carneskog, J., Dahl, I. M. S., Dybedal, I., Grimfors, G., Kanter‐Lewensohn, L. R., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 303
Prognosis of hematologic malignancies does not predict intensive care unit mortality
Massion, P. B., Dive, A., Doyen, C., Bulpa, P., Jamart, J., Bosly, A., & Installé, E. (2002) · Critical Care Medicine · doi:10.1097/00003246-200210000-00014 · Cited by 301
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Keilholz, U., Letsch, A., Busse, A., Asemissen, A. M., Bauer, S., Blau, I. W., Hofmann, W., Uharek, L., Thiel, E., & Scheibenbogen, C. (2009) · Blood · doi:10.1182/blood-2009-02-202598 · Cited by 300
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes
Bowen, D., Culligan, D. J., Jowitt, S. N., Kelsey, S. M., Mufti, G. J., Oscier, D. G., Parker, J., & of the UK MDS Guidelines Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.03907.x · Cited by 300
Self-citation
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
Jädersten, M., Malcovati, L., Dybedal, I., Porta, M. G. D., Invernizzi, R., Montgomery, S., Pascutto, C., Porwit‐MacDonald, A., Cazzola, M., & Hellström‐Lindberg, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4906 · Cited by 299
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients
Germing, U., Gattermann, N., Strupp, C., Aivado, M. A., & Aul, C. (2000) · Leukemia Research · doi:10.1016/s0145-2126(00)00088-6 · Cited by 296
Self-citation
Myelodysplastic Syndromes
Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Castro, C. M. D., Deeg, H. J., Foran, J. M., Gaensler, K. M. L., Garcia‐Manero, G., Gore, S. D., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0005 · Cited by 287
Self-citation
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Platzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30615-0 · Cited by 292
Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Yan, C., Liu, D., Liu, K., Xu, L., Liu, Y., Chen, H., Han, W., Wang, Y., Qin, Y., & Huang, X. (2012) · Blood · doi:10.1182/blood-2011-09-380386 · Cited by 289
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
Pellagatti, A., Cazzola, M., Giagounidis, A. A. N., Perry, J., Malcovati, L., Porta, M. G. D., Jädersten, M., Killick, S. B., Verma, A. K., Norbury, C. J., et al. (2010) · Leukemia · doi:10.1038/leu.2010.31 · Cited by 279
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
Traina, F., Visconte, V., Elson, P. J., Tabarroki, A., Jankowska, A., Hasrouni, E., Sugimoto, Y., Szpurka, H., Makishima, H., O'Keefe, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.269 · Cited by 296
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
Koreth, J., Pidala, J., Pérez, W. S., Deeg, H. J., Garcia‐Manero, G., Malcovati, L., Cazzola, M., Park, S., Itzykson, R., Adès, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8652 · Cited by 287
Self-citation
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
Deeg, H. J., Storer, B. E., Slattery, J. T., Anasetti, C., Doney, K., Hansen, J. A., Kiem, H., Martin, P. J., Petersdorf, E. W., Radich, J. P., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0527 · Cited by 283
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
Malcovati, L., Porta, M. G. D., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044602 · Cited by 282
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Pang, W. W., Pluvinage, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., Schrier, S. L., Park, C. Y., & Weissman, I. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222861110 · Cited by 277
Self-citation

Authors: Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., & Bennett, J.
Affiliations: Tokyo Medical University (JP)
From the Hematology Divisions of Stanford University Medical Center, Stanford, CA; the Rochester Medical Center, Rochester, NY; the University of Chicago, Chicago, IL; Centre Hospitalier Universitaire, Lille, France; Hospital La Fe, Valencia, Spain; Hospital Vall d'Hebron, Barcelona, Spain; the Royal Bournemouth Hospital, Bournemouth, UK; the Tokyo Medical College, Tokyo, Japan; the Heinrich Heine University, Dusseldorf, Germany; and the King's College Hospital, London, UK.
ORCID: Greenberg, Peter
Cox, Christopher
Fenaux, Pierre
Morel, Pierre
Sanz, Guillermo
Sanz, Miguel
Oscier, David
Ohyashiki, Kazuma
Toyama, Keisuke
Mufti, Ghulam
Bennett, John
Venue: Blood
Publisher: American Society of Hematology
Published: 1997-03-15
Volume: 89
Issue: 6
Pages: 2079-2088
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood.v89.6.2079
OpenAlex: W187238933
Cited by: 4,427
References: 33
Citations by year: 2026: 45 · 2025: 69 · 2024: 93 · 2023: 124 · 2022: 131 · 2021: 155 · 2020: 167 · 2019: 144 · 2018: 174 · 2017: 226 · 2016: 183 · 2015: 205 · 2014: 232 · 2013: 253 · 2012: 256
FWCI: 36.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: myelodysplastic syndrome, prognostic score, International Prognostic Scoring System, risk stratification, bone marrow cytogenetics, acute myeloid leukemia transformation, bone marrow blasts, cytopenia, survival, del(5q), del(20q)
MeSH terms: Acute Disease, Adolescent, Adult, Age Factors, Aged, Bone Marrow, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Sex Factors, Multivariate Analysis, Survival Analysis, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks